Lumexa Imaging Forms Strategic Joint Venture with Hospital for Special Surgery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Lumexa Imaging announced the formation of a strategic joint venture with Hospital for Special Surgery. The collaboration represents Lumexa Imaging's ninth joint venture. Lumexa Imaging and HSS plan to expand access to advanced outpatient imaging services across the New York City metro area.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LMRI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LMRI
Wall Street analysts forecast LMRI stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.510
Low
22.00
Averages
22.71
High
23.00
Current: 7.510
Low
22.00
Averages
22.71
High
23.00
About LMRI
Lumexa Imaging Holdings, Inc. is a national provider of diagnostic imaging services. The Company offers a range of advanced imaging services (MRI, CT and PET scans) and routine diagnostic and screening imaging services (X-ray, ultrasound and mammography). The Company’s segments include Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The Outpatient segment consists of imaging centers that are owned or operated by it (either wholly owned or via unconsolidated affiliate), where it performs the imaging scan and provides the radiologist’s interpretation service. The Professional segment consists of professional interpretation services, where the imaging scan itself is performed at the hospital or point of care and not by it or its unconsolidated affiliates. The Company and its affiliates operate outpatient imaging center footprint in the United States, spanning 184 centers across 13 states and includes eight joint venture partnerships with health systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lumexa Imaging Holdings Reports Q1 2026 Earnings Highlights
- Revenue Growth: Lumexa Imaging reported consolidated revenues of $253 million in Q1 2026, reflecting a 3% year-over-year increase, demonstrating the company's resilience amid seasonal and weather-related challenges, which bolsters market confidence.
- EBITDA Performance: Adjusted EBITDA stood at $51.2 million with a margin of 20.3%, and despite weather impacts, management expects full-year EBITDA to range between $234 million and $242 million, indicating confidence in future profitability.
- Strategic Expansion: The company completed 2 acquisitions and opened 2 new sites in Q1, progressing towards its goal of establishing 8 to 10 new locations this year, showcasing its proactive approach to market expansion and growth.
- Leadership Changes: Lumexa Imaging welcomed Kyle Lynch as the new Chief Growth Officer and Rikki Mondo as Chief Enterprise Operations Officer, further strengthening its management team and laying a solid foundation for long-term development.
See More
Lumexa Imaging Q1 Earnings Beat Expectations
- Profitability Improvement: Lumexa Imaging Holdings, Inc. reported a Q1 non-GAAP EPS of $0.18, beating expectations by $0.06, indicating a significant enhancement in profitability and reflecting increased competitiveness in the market.
- Revenue Growth: The company reported revenue of $252.2 million, exceeding expectations by $1.01 million, demonstrating sustained demand in the medical imaging sector and further solidifying its market position.
- Net Income Turnaround: The net income for Q1 was $1.7 million, a turnaround from a net loss of $7.7 million in the same period last year, showcasing successful cost control and operational efficiency, which boosts investor confidence.
- Stable Adjusted EBITDA: Adjusted EBITDA reached $51.2 million, slightly up from $51.0 million year-over-year, with an EBITDA margin of 20.3%, indicating that the company maintains stability in profitability and operational efficiency.
See More
Lumexa Imaging to Release Q1 2026 Financial Results
- Earnings Release Schedule: Lumexa Imaging will announce its Q1 2026 financial and operational results after market close on May 12, 2026, which is expected to provide investors with critical performance data and future outlook.
- Conference Call Details: The company will host a conference call and live webcast at 5:00 PM ET on the same day to discuss the financial results in depth, aiming to enhance transparency and investor confidence.
- Company Scale and Impact: As one of the largest outpatient imaging service providers in the U.S., Lumexa Imaging employs over 5,000 team members and operates 185 imaging centers, having conducted approximately 4 million outpatient procedures in 2025, showcasing its strong market position in medical imaging.
- Technology and Service Advantages: The company is committed to delivering best-in-class clinical excellence, operational efficiency, and state-of-the-art technology, making it the partner of choice for health systems and radiologists, thereby further solidifying its competitive edge in the industry.
See More
Johnson Fistel Investigates Lumexa Imaging for Potential Investor Claims
- Financial Loss Disclosure: On March 26, 2026, Lumexa Imaging reported a net loss for both Q4 and the full year of 2025, which significantly undermined investor confidence and led to a sharp decline in stock price during trading.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Lumexa Imaging's executives violated federal securities laws, potentially allowing investors who suffered losses from purchasing the company's securities to seek recovery through legal channels.
- Investor Rights Protection: The law firm focuses on representing individual and institutional investors in shareholder derivative and securities class action lawsuits, aiming to provide legal support and protect the rights of affected investors.
- Past Performance Review: In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms, successfully recovering approximately $90.725 million for clients, demonstrating its effectiveness in advocating for investor rights.
See More
Lumexa Imaging Reports Q4 Loss and Revenue Growth
- Financial Overview: Lumexa Imaging reported a net loss of $28.7 million in Q4, up from $25.1 million a year earlier, despite a 7.9% year-over-year revenue increase to $267.7 million, indicating potential in revenue growth but the widening loss may dampen investor confidence.
- Adjusted EBITDA Growth: The company achieved an adjusted EBITDA of $63.8 million, an 18.6% increase from $53.7 million last year, with an adjusted EBITDA margin of 23.8%, demonstrating significant progress in cost control and operational efficiency, although overall financial health still requires improvement.
- Leverage Reduction: Lumexa Imaging successfully reduced its leverage from 5.5 times to 3.5 times, resulting in over $50 million in annual cash savings, which enhances the company's financial flexibility and provides a stronger foundation for future investments and expansion.
- 2026 Outlook: The company reiterated its financial outlook for 2026, expecting consolidated revenues between $1.045 billion and $1.097 billion, with adjusted EBITDA projected at $234 million to $242 million, although the addition of public company costs lowers the adjusted EBITDA growth rate from 7% to 4%, potentially impacting market expectations for future growth.
See More
LUMEXA IMAGING HOLDINGS INC - 2026 REVENUE PROJECTIONS: CONSOLIDATED REVENUES BETWEEN $1.045 AND $1.097 BILLION
Company Overview: LUMEXA Imaging Holdings is a company focused on imaging technologies and solutions.
Financial Performance: The company reported consolidated revenues ranging from $1.045 billion to $1.097 billion for the year 2026.
See More
Lumexa Imaging Holdings Reports Q1 2026 Earnings Highlights
- Revenue Growth: Lumexa Imaging reported consolidated revenues of $253 million in Q1 2026, reflecting a 3% year-over-year increase, demonstrating the company's resilience amid seasonal and weather-related challenges, which bolsters market confidence.
- EBITDA Performance: Adjusted EBITDA stood at $51.2 million with a margin of 20.3%, and despite weather impacts, management expects full-year EBITDA to range between $234 million and $242 million, indicating confidence in future profitability.
- Strategic Expansion: The company completed 2 acquisitions and opened 2 new sites in Q1, progressing towards its goal of establishing 8 to 10 new locations this year, showcasing its proactive approach to market expansion and growth.
- Leadership Changes: Lumexa Imaging welcomed Kyle Lynch as the new Chief Growth Officer and Rikki Mondo as Chief Enterprise Operations Officer, further strengthening its management team and laying a solid foundation for long-term development.
See More
Lumexa Imaging Q1 Earnings Beat Expectations
- Profitability Improvement: Lumexa Imaging Holdings, Inc. reported a Q1 non-GAAP EPS of $0.18, beating expectations by $0.06, indicating a significant enhancement in profitability and reflecting increased competitiveness in the market.
- Revenue Growth: The company reported revenue of $252.2 million, exceeding expectations by $1.01 million, demonstrating sustained demand in the medical imaging sector and further solidifying its market position.
- Net Income Turnaround: The net income for Q1 was $1.7 million, a turnaround from a net loss of $7.7 million in the same period last year, showcasing successful cost control and operational efficiency, which boosts investor confidence.
- Stable Adjusted EBITDA: Adjusted EBITDA reached $51.2 million, slightly up from $51.0 million year-over-year, with an EBITDA margin of 20.3%, indicating that the company maintains stability in profitability and operational efficiency.
See More
Lumexa Imaging to Release Q1 2026 Financial Results
- Earnings Release Schedule: Lumexa Imaging will announce its Q1 2026 financial and operational results after market close on May 12, 2026, which is expected to provide investors with critical performance data and future outlook.
- Conference Call Details: The company will host a conference call and live webcast at 5:00 PM ET on the same day to discuss the financial results in depth, aiming to enhance transparency and investor confidence.
- Company Scale and Impact: As one of the largest outpatient imaging service providers in the U.S., Lumexa Imaging employs over 5,000 team members and operates 185 imaging centers, having conducted approximately 4 million outpatient procedures in 2025, showcasing its strong market position in medical imaging.
- Technology and Service Advantages: The company is committed to delivering best-in-class clinical excellence, operational efficiency, and state-of-the-art technology, making it the partner of choice for health systems and radiologists, thereby further solidifying its competitive edge in the industry.
See More
Johnson Fistel Investigates Lumexa Imaging for Potential Investor Claims
- Financial Loss Disclosure: On March 26, 2026, Lumexa Imaging reported a net loss for both Q4 and the full year of 2025, which significantly undermined investor confidence and led to a sharp decline in stock price during trading.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Lumexa Imaging's executives violated federal securities laws, potentially allowing investors who suffered losses from purchasing the company's securities to seek recovery through legal channels.
- Investor Rights Protection: The law firm focuses on representing individual and institutional investors in shareholder derivative and securities class action lawsuits, aiming to provide legal support and protect the rights of affected investors.
- Past Performance Review: In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms, successfully recovering approximately $90.725 million for clients, demonstrating its effectiveness in advocating for investor rights.
See More
Lumexa Imaging Reports Q4 Loss and Revenue Growth
- Financial Overview: Lumexa Imaging reported a net loss of $28.7 million in Q4, up from $25.1 million a year earlier, despite a 7.9% year-over-year revenue increase to $267.7 million, indicating potential in revenue growth but the widening loss may dampen investor confidence.
- Adjusted EBITDA Growth: The company achieved an adjusted EBITDA of $63.8 million, an 18.6% increase from $53.7 million last year, with an adjusted EBITDA margin of 23.8%, demonstrating significant progress in cost control and operational efficiency, although overall financial health still requires improvement.
- Leverage Reduction: Lumexa Imaging successfully reduced its leverage from 5.5 times to 3.5 times, resulting in over $50 million in annual cash savings, which enhances the company's financial flexibility and provides a stronger foundation for future investments and expansion.
- 2026 Outlook: The company reiterated its financial outlook for 2026, expecting consolidated revenues between $1.045 billion and $1.097 billion, with adjusted EBITDA projected at $234 million to $242 million, although the addition of public company costs lowers the adjusted EBITDA growth rate from 7% to 4%, potentially impacting market expectations for future growth.
See More
LUMEXA IMAGING HOLDINGS INC - 2026 REVENUE PROJECTIONS: CONSOLIDATED REVENUES BETWEEN $1.045 AND $1.097 BILLION
Company Overview: LUMEXA Imaging Holdings is a company focused on imaging technologies and solutions.
Financial Performance: The company reported consolidated revenues ranging from $1.045 billion to $1.097 billion for the year 2026.
See More
